Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Multiple Myeloma 43Leukemia, Myeloid, Acute 25Recurrence 21Lymphoma, Large B-Cell, Diffuse 12Sarcoma 8Neoplasms, Plasma Cell 5Neoplasm Metastasis 5Lymphoma 5Glioblastoma 5Ovarian Neoplasms 4Neurofibrosarcoma 4Neoplasms 4Melanoma 4Lymphoma, Non-Hodgkin 4Endometrial Neoplasms 4Colorectal Neoplasms 4Triple Negative Breast Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Lymphoma, T-Cell, Peripheral 3Lymphoma, Extranodal NK-T-Cell 3Lymphoma, B-Cell 3Liposarcoma 3Glioma 3Carcinoma, Non-Small-Cell Lung 3Carcinoma 3Waldenstrom Macroglobulinemia 2Thymoma 2Sarcoma, Alveolar Soft Part 2Rhabdoid Tumor 2

Interventions

Cisplatin 12Everolimus 10Nivolumab 8Etoposide 8Temozolomide 6Carboplatin 6atezolizumab 5Irinotecan 5Ipilimumab 5Fluorouracil 5Bevacizumab 5pembrolizumab 4lutetium Lu 177 dotatate 4Capecitabine 4avelumab 3Paclitaxel 3IFL protocol 3surufatinib 2sintilimab 2dostarlimab 2cabozantinib 2belinostat 2azaspirane 2Topotecan 2Radiosurgery 2Positron Emission Tomography Computed Tomography 2PE regimen 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Magnetic Resonance Imaging 2Leucovorin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Neuroendocrine × selinexor × Clear all
NCT02250885 2019-09-17

KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors

Gabrail Cancer Center Research

Phase 2 Completed
14 enrolled
Endocrine

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡